PEGylation Reagents .pdf
Original filename: PEGylation Reagents.pdf
This PDF 1.5 document has been generated by Microsoft? Office Word 2007, and has been sent on pdf-archive.com on 18/10/2019 at 08:13, from IP address 198.11.x.x.
The current document download page has been viewed 64 times.
File size: 98 KB (2 pages).
Privacy: public file
Download original PDF file
The Applications of PEGylation Reagents
As an industry biotechnology company, Biochempeg offers its customers new
polymers for a variety of R&D platforms. Biochempeg provides catalogues/customized
standards for active polyethylene glycol reagents for colleges, research centers,
biotechnology and pharmaceutical R&D companies. Biochempeg supplies a wide
range of reactive polymers to respond quickly to customer needs and provide
The Application of PEGylation Reagents
PEGylated protein drugs: PEGylated protein drugs can extend drug half-life,
reduce immunogenicity, while maximizing the retention of its biological
activity. As a therapeutic drug, polyethylene glycol (PEG) modified proteins are
more effective than unmodified proteins. The modification pathway of
PEGylated protein drug mainly includes amino modification (including
acylation modification of N-terminal amino group, acylation modification of
lysine side chain amino group, alkylation modification of N-terminal amino
group), carboxyl modification, thiol modification, and the like. At present, the
research on PEGylated protein drugs at home and abroad mainly focuses on
adenosine deaminase, asparaginase, interferon, granulocyte colonystimulating factor, interleukin, etc. More than 40 drugs are undergoing clinical
PEGylated peptide based compounds: PEGylated peptide based compounds,
such as the PEGylated products of furrow calcitonin, epidermal growth factor,
have longer half-life and higher biological activity than the parent drug. In
particular, peptide compounds are easier to achieve than proteins in fixedpoint modification of polyethylene glycol. The most common application in
the PEGylation study of peptide compounds is mPEG.
PEGylated liposomes: Ordinary immunoliposomes are limited in their ability to
be cleared due to their short half-life in the blood, which limits their
development. PEGylated long-circulating liposomes (stealth
liposomes) increase the blood circulation time of liposomes, which not only
can escape the capture of the reticuloendothelial system, but also improve the
passive targeting. It has been widely used in liposome pharmaceutical
PEGylated organic small molecule drugs: many small molecule drugs,
especially the anti-tumor drugs, use PEGylation technology to improve its
biocompatibility. The polyethylene glycol (PEG) supported small molecules can
transfer many of its excellent properties to the conjugate which make the
polymer has excellent biocompatibility. Thus, the polymer can be dissolved in
the tissue fluid, and can be quickly excreted by the body without any toxic side
effects. Many anti-tumor drugs are modified by high molecular weight PEG to
achieve passive targeted administration of tumor tissue.
Other applications: PEGylated affinity ligands and cofactors are used in
aqueous two-phase distribution systems for the purification and analysis of
biological macromolecules and cells. PEGylated sugars can be used as new
drug materials and drug carriers. Oligonucleotide PEGylation can increase
solubility, resistance to nucleases, and cell membrane permeability. Biomaterial
PEGylation reduces thrombus formation and reduces protein and cell adhesion.